A new vaccine to prevent triple-negative breast cancer
Official title: TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCERIDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11122378 · Data updated 2026-11-12
This study is testing a new mRNA vaccine designed to help prevent triple-negative breast cancer, which is a tough type of breast cancer, by boosting the immune system to fight it early on, and it's aimed at people who are at risk of developing this cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | June 17, 2024 |
| Project end | December 16, 2025 |
| Funding year | 2024 |
| Award (this year) | $764,880 |
| NIH project number | 75N91024D00005-0-759102400002-1 |
| Project ID | NIH-11122378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for developing triple-negative breast cancer, particularly those with a family history or genetic predisposition.
✕Less likely to help
Patients who already have a diagnosis of triple-negative breast cancer or those with other types of breast cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel mRNA vaccine aimed at preventing triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The approach involves targeting specific proteins that are overexpressed in TNBC, using a multivalent vaccine that combines multiple antigens to elicit a stronger immune response. The vaccine will be tested in animal models to evaluate its effectiveness in preventing the onset of TNBC. By targeting the disease early, the research aims to improve outcomes for patients at risk of developing this cancer.
Why it matters
Potential benefit: If successful, this research could lead to a preventive vaccine that significantly reduces the incidence of triple-negative breast cancer.
How similar studies have gone: Other research has shown promise in developing vaccines targeting specific antigens in various cancers, suggesting that this approach could be effective for TNBC as well.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Rao, Chinthalapally V. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rao, Chinthalapally V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.